Cerus Corp. PT Raised to $7.50 (CERS)
Research analysts at Wedbush upped their price objective on shares of Cerus Corp. (NASDAQ:CERS) from $6.00 to $7.50 in a report released on Monday, Analyst Ratings Network reports. The firm currently has an “outperform” rating on the stock. Wedbush’s price objective suggests a potential upside of 11.61% from the stock’s previous close.
Shares of Cerus Corp. (NASDAQ:CERS) traded up 5.99% during mid-day trading on Monday, hitting $6.72. The stock had a trading volume of 946,955 shares. Cerus Corp. has a 52-week low of $2.68 and a 52-week high of $6.77. The stock’s 50-day moving average is $5.66 and its 200-day moving average is $5.08. The company’s market cap is $468.6 million.
Separately, analysts at Cantor Fitzgerald raised their price target on shares of Cerus Corp. (NASDAQ:CERS) from $6.00 to $7.00 in a research note to investors on Thursday, August 1st. They now have a “buy” rating on the stock.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.